Page 2 - பார்மா உளவுத்துறை மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பார்மா உளவுத்துறை மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பார்மா உளவுத்துறை மையம் Today - Breaking & Trending Today

CAR-T therapy leads Singapore medical tourism within APAC

CAR-T therapy leads Singapore medical tourism within APAC
12 April 2021 | Analysis
With the approval of Novartis’ Kymriah, Singapore is becoming a popular medical tourism destination within APAC: says GlobalData
Photo Credit: GlobalData
The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are gaining traction. With the approval of Novartis’ Kymriah, Singapore is now all set to deliver the transformative treatment for cancers and takes the lead in medical tourism within Asia-Pacific (APAC), says GlobalData, a leading data and analytics company.
In March 2021, Novartis received approval for Kymriah for adult r/r diffuse large B-cell lymphoma DLBCL (DLBCL) patients and young adult r/r B-cell acute lymphoblastic leukemia (ALL) patients. Kymriah will be the first CAR-T therapy to be approved in Southeast Asia. ....

National University Hospital , Singapore General , South Korea , Novarti Kymriah , Bhavani Nelavelly , Globaldata Pharma Intelligence Center , Pharma Analyst , Southeast Asia , Pharma Intelligence Center , Singapore General Hospital , Novartis Kymriah , Cart Therapy , தேசிய பல்கலைக்கழகம் மருத்துவமனை , சிங்கப்பூர் ஜநரல் , தெற்கு கொரியா , பார்மா ஆய்வாளர் , தென்கிழக்கு ஆசியா , பார்மா உளவுத்துறை மையம் , சிங்கப்பூர் ஜநரல் மருத்துவமனை , வண்டி சிகிச்சை ,

Huntington's Disease - Competitive Landscape in 2021

Huntington's Disease - Competitive Landscape in 2021
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Huntingtons Disease , Pharma Intelligence Center , Competitive Advantage , Commercial Assessment , Pharma Companies , பார்மா உளவுத்துறை மையம் , வணிகரீதியானது மதிப்பீடு , பார்மா நிறுவனங்கள் ,

Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021

Summary "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.New York, March 12, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" - https://www.reportlinker.com/p06035016/?utm source=GNW CD-19 and CD-20 inhibitors are a major focus of drug developers.There are 387 drugs in the pipeline, 95x% 0f which are in early-stage.Big Pharma companies dominates R&D in this indication with Roche leading the way. The addition of several high-priced therapies is expected to drive market growth, but cost savings due to biosimilar drugs will act as a strong barrier to market growth.This reports provides a data-driven overview of the current and future competitive landscape in DLBCL therapeutics.ScopeComponents of the r ....

Pharma Intelligence Center , Diffuse Largeb Cell Lymphoma , Competitive Landscape , Competitive Advantage , Commercial Assessment , Big Pharma Companies , பார்மா உளவுத்துறை மையம் , போட்டி இயற்கை , வணிகரீதியானது மதிப்பீடு , பெரியது பார்மா நிறுவனங்கள் ,

Psoriasis - Competitive Landscape in 2020

Summary "Psoriasis - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.New York, March 12, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report "Psoriasis - Competitive Landscape in 2020" - https://www.reportlinker.com/p06035014/?utm source=GNW Interleukin and tumor necrosis factor inhibitors are the major focus of drug developers.There are 350 drugs in the pipeline, 89% 0f which are in early-stage.Big pharma dominates R&D in this indication. Addition of several high-priced therapies are expected to drive the market growth, but emergence of biosimilars to all the marketed brands is expected to act as a strong barrier to market growth.This reports provides a data-driven overview of the current and future competitive landscape in Psoriasis therapeutics.ScopeComponents of the report include Disease epidemiology- Ma ....

Pharma Intelligence Center , Commercial Assessment , Competitive Advantage , பார்மா உளவுத்துறை மையம் , வணிகரீதியானது மதிப்பீடு ,

Gouty Arthritis (Gout) - Competitive Landscape in 2021

Gouty Arthritis (Gout) - Competitive Landscape in 2021
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Gouty Arthritis , Pharma Intelligence Center , Commercial Assessment , Competitive Advantage , Pharma Companies , கௌதி கீல்வாதம் , பார்மா உளவுத்துறை மையம் , வணிகரீதியானது மதிப்பீடு , பார்மா நிறுவனங்கள் ,